Tradestie Institutional Equity Comparison Engine · Market Close May 07, 2026

EXPI vs EKSO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EXPI Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–1 Matrix Metrics)

EXPI Overall Winner 6-Pillar Tally: EXPI 6 – 0 EKSO Matrix Metrics: EXPI 7 – 1 EKSO

As of May 07, 2026, eXp World Holdings, Inc. (EXPI) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EXPI carries a Unified Composite Score of 67.2/100 (BUY) at $6.74 (N/M Forward P/E, -1.1% operating margin), whereas EKSO carries 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EXPI vs EKSO
EXPI NASDAQ Head-to-Head Winner
eXp World Holdings, Inc. Common Stock
Real Estate Agents & Managers (For Others)
$6.74
+3.37% 1D
Market Cap $1.0B
TTM Revenue $4.77B
Forward P/E N/M
Beta / 30D Vol 1.23β · 39% Vol
Unified Composite Score
67.2 / 100 BUY
Tech 75.0 Fund 67.0 Flow 67.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 59
RSI-14: 59.4 · SMA20: $6.38 · SMA50: $6.28
EKSO NASDAQ
Ekso Bionics Holdings, Inc. Common Stock
General Industrial Machinery & Equipment, Nec
$11.80
+0.08% 1D
Market Cap $42.0M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 2.16β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 60
RSI-14: 60.4 · SMA20: $10.56 · SMA50: $10.65

6-Pillar Scorecard Institutional Category Breakdown (EXPI 6 – 0 EKSO)

Columns: Metric · EXPI · EKSO
1. Valuation Multiples EXPI
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.2x 3.3x
2. Growth & Scale EXPI
Revenue Growth (YoY) +8.5% -38.3%
Earnings Growth (YoY) +39.8% +0.0%
TTM Revenue (USD) $4.77B $13M
Market Cap $1.0B $42.0M
3. Profitability & Quality EXPI
Gross Margin 7.0% 53.5%
Operating Margin -1.1% -119.7%
Net Profit Margin -0.5% -91.4%
Return on Equity (ROE) -10.2% -107.6%
4. Balance Sheet & Cash Flow EXPI
Cash Generation (TTM) $90M -$11M EBITDA
Cash Flow Margin 1.9% -86.0% EBITDA Mgn
Net Cash / Leverage $1.51 Book/Sh · -10.2% ROE $2.54 Book/Sh · -107.6% ROE
Dividend Yield 3.18% None (0.00%)
5. Options & Positioning EXPI
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 61.9% (<1st %ile) N/A (N/A)
Put/Call OI Skew 0.10x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat EXPI
OpEx & R&D Intensity 8.1% of Rev ($387M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Real Estate Services Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EXPI (7) vs EKSO (1)
Institutional Metric EXPI EKSO Criterion Row Edge
Market Capitalization
Scale
$1.0B $42.0M Larger Scale EXPI
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+8.5% -38.3% Higher Growth EXPI
Operating Margin (TTM)
Profitability
-1.1% -119.7% Higher Margin EXPI
Net Profit Margin
Profitability
-0.5% -91.4% Higher Margin EXPI
Return on Equity (ROE)
Capital Efficiency
-10.2% -107.6% Higher ROE EXPI
52-Week Range Position
Momentum
16% ($6–$12) 87% ($0–$14) Stronger Trend EKSO
Beta / 30D Volatility
Risk Regime
1.23β · 39% Vol 2.16β · 76% Vol Lower Realized Risk EXPI
Unified Institutional Score
Composite Signal
67.2 / 100 (BUY) 58.1 / 100 (HOLD) Higher Composite EXPI
Trailing 12M Revenue (USD)
Operating Scale
$4.77B $13M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
7.0% 53.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.2x EV/Rev N/M PEG · 3.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$90M ($1.51 Book/Sh · -10.2% ROE) -$11M EBITDA ($2.54 Book/Sh · -107.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EKSO +19.78 pp
EXPI: +5.75% · EKSO: +25.53%
3M Horizon EKSO +55.78 pp
EXPI: -29.85% · EKSO: +25.93%
6M Horizon EKSO +169.24 pp
EXPI: -37.87% · EKSO: +131.37%
1Y Horizon EKSO +109.59 pp
EXPI: -27.91% · EKSO: +81.68%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EXPI vs EKSO. Trailing 12-month operating profitability (EXPI -1.1% vs EKSO -119.7%) and valuation multiples (EXPI N/M vs EKSO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EXPI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.77B
Gross Margin7.0%
Op. Margin-1.1%
ROE / Fwd P/E-10.2% · N/M
EKSO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross Margin53.5%
Op. Margin-119.7%
ROE / Fwd P/E-107.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EXPI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 61.9%
IV Percentile <1st %ile
Put/Call OI Skew 0.10x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EXPI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EKSO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EKSO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EXPI Moat Profile Cyclical / Execution-Driven Positioning
Real Estate Services Operator
Competes within the Real Estate Services value chain with $1.0B market capitalization and -1.1% operating margin.
OpEx & R&D Reinvestment 8.1% of Rev ($387M)
90D Engineering Disclosures 0 Published
EKSO Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $42.0M market capitalization and -119.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EXPI vs EKSO Key Questions & Quantitative Answers

As of May 07, 2026, eXp World Holdings, Inc. (EXPI) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EXPI carries a Unified Composite Score of 67.2/100 (BUY) at $6.74 (N/M Forward P/E, -1.1% operating margin), whereas EKSO carries 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin). Technically, EXPI sits in a Neutral phase (RSI 59.4, UNCLASSIFIED options structure) and EKSO sits in a Markup phase (RSI 60.4, UNCLASSIFIED options structure).

EXPI leads the Growth & Scale pillar: EXPI posts +8.5% YoY revenue growth and +39.8% YoY earnings growth on $4.77B TTM revenue (7.0% gross margin, -1.1% operating margin), compared with EKSO at -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin). On trailing 12-month operating scale, EXPI generates $4.77B in USD-normalized revenue versus $13M for EKSO. In operating R&D and SG&A reinvestment, EXPI deploys 8.1% of Rev ($387M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EKSO.

EXPI screens cheaper on headline valuation multiples. EXPI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.2x EV/Revenue (1.9% FCF margin), whereas EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EXPI (-10.2% ROE) versus EKSO (-107.6% ROE) capital efficiency.

In options market volatility and institutional positioning, EXPI carries 61.9% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.10x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.23β · 39% Vol realized risk). By comparison, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of May 07, 2026. For educational research only; not investment advice.